异甘草酸镁联合恩替卡韦对乙肝肝硬化的治疗作用研究

Study on the therapeutic effect of magnesium isoglycyrrhizinate combined with entecavir on hepatitis B cirrhosis

目的探讨异甘草酸镁联合恩替卡韦治疗乙型肝炎(乙肝)肝硬化的临床效果.方法96例乙肝肝硬化患者,随机分为恩替卡韦组和异甘草酸镁联合恩替卡韦组,各48例.恩替卡韦组患者采取恩替卡韦治疗,异甘草酸镁联合恩替卡韦组患者在恩替卡韦组基础上联合异甘草酸镁治疗.比较两组患者临床疗效、病情改善时间、住院时间、治疗前后肝功能指标、生活质量评分以及不良反应发生情况.结果异甘草酸镁联合恩替卡韦组患者治疗总有效率为100.00%,明显高于恩替卡韦组的66.67%,差异具有统计学意义(P<0.05).治疗前,两组患者生活质量评分、总胆红素(TBIL)、谷草转氨酶(AST)、谷丙转氨酶(ALT)水平比较,差异无统计学意义(P>0.05);治疗后,两组患者生活质量评分、TBIL、AST、ALT水平均明显优于治疗前,且异甘草酸镁联合恩替卡韦组明显优于恩替卡韦组,差异均具有统计学意义(P<0.05).异甘草酸镁联合恩替卡韦组患者病情改善时间、住院时间分别为(10.46±1.21)、(11.21±0.14)d,均明显短于恩替卡韦组的(13.13±2.78)、(16.89±1.21)d,差异均具有统计学意义(P<0.05).异甘草酸镁联合恩替卡韦组患者不良反应发生率为8.33%,恩替卡韦组患者不良反应发生率为8.33%,比较差异无统计学意义(P>0.05).结论异甘草酸镁联合恩替卡韦治疗乙肝肝硬化效果显著,可有效改善患者肝功能,提高生活质量,且无严重不良反应,安全性高,值得临床推广与应用.

Objective To discuss the clinical effect of magnesium isoglycyrrhizinate combined with entecavir on hepatitis B cirrhosis.Methods A total of 96 hepatitis B cirrhosis patients were randomly divided into entecavir group and magnesium isoglycyrrhizinate combined with entecavir group,with 48 cases in each group.Entecavir group was treated with entecavir,and magnesium isoglycyrrhizinate combined with entecavir group was treated with magnesium isoglycyrrhizinate combined with entecavir.The clinical efficacy,improvement of disease condition,hospitalization time,liver function indexes before and after treatment,quality of life score and occurrence of adverse reactions was compared between the two groups.Results The total effective rate of treatment was 100.00% in magnesium isoglycyrrhizinate combined with entecavir group,which was obviously higher than 66.67% in entecavir group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in quality of life score,total bilirubin(TBIL),aspartate aminotransferase(AST)and alanine aminotransferase(ALT)between the two groups(P>0.05).After treatment,the quality of life score,and levels of TBIL,AST and ALT in the two groups was obviously better than those before treatment,and magnesium isoglycyrrhizinate combined with entecavir group was obviously better than entecavir group.Their difference was statistically significant(P<0.05).The improvement time of disease condition was(10.46±1.21)and(11.21±0.14)d in magnesium isoglycyrrhizinate combined with entecavir group,which was obviously shorter than(13.13±2.78)and(16.89±1.21)d in entecavir group,and their difference was statistically significant(P<0.05).The incidence of adverse reactions was 8.33% in magnesium isoglycyrrhizinate combined with entecavir group,which was 8.33%in entecavir group,and the difference was not statistically significant(P>0.05).Conclusion Magnesium isoglycyrrhizinate combined with entecavir shows remarkable effect in the treatment of hepatitis B cirrhosis.It can effectively improve the liver function,improve the quality of life without serious adverse reactions,and has high safety.It is worthy of clinical promotion and application.